Hagop Youssoufian
Corporate Officer/Principal at VERASTEM, INC.
Profile
Hagop Youssoufian is a Member of the American Society for Clinical Investigation.
He is also the Head-Medical Strategy at Verastem, Inc. since 2018 and the Chief Medical Officer at Oncxerna Therapeutics, Inc. since 2020.
Previously, he served as the Chief Medical Officer at ImClone LLC and Progenics Pharmaceuticals, Inc. from 2013 to 2014.
He was also the Chief Medical Officer at DNIB Unwind, Inc. and Alaunos Therapeutics, Inc. from 2011 to 2013.
Additionally, he held positions as an Associate Professor at Baylor College of Medicine and an Assistant Professor at Harvard Medical School.
Dr. Youssoufian completed his undergraduate degree at Boston College and obtained graduate and doctorate degrees from UMass Chan Medical School.
Hagop Youssoufian active positions
| Companies | Position | Start |
|---|---|---|
| VERASTEM, INC. | Corporate Officer/Principal | 18/01/2017 |
American Society for Clinical Investigation
 American Society for Clinical Investigation BiotechnologyHealth Technology American Society for Clinical Investigation engages as a medical honor society. It focuses on physician-scientists in research, clinical care, and medical education. The company was founded by Samuel J. Meltzer in 1908 and is headquartered in Ann Arbor, MI. | Corporate Officer/Principal | - |
Oncxerna Therapeutics, Inc.
 Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | Chief Tech/Sci/R&D Officer | 08/07/2020 |
Former positions of Hagop Youssoufian
| Companies | Position | End |
|---|---|---|
| PROGENICS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 18/09/2014 |
| ALAUNOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/04/2013 |
| Baylor College of Medicine | Corporate Officer/Principal | - |
| Harvard Medical School | Corporate Officer/Principal | - |
| DNIB UNWIND INC | Chief Tech/Sci/R&D Officer | - |
Training of Hagop Youssoufian
| Boston College | Undergraduate Degree |
| UMass Chan Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| VERASTEM, INC. | Health Technology |
| Private companies | 5 |
|---|---|
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Progenics Pharmaceuticals, Inc.
 Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
DNIB Unwind, Inc.
 DNIB Unwind, Inc. BiotechnologyHealth Technology DNIB Unwind, Inc. develops biopharmaceutical preparations. The company was founded by Omid C. Farokhzad and Robert S. Langer on May 19, 2006 and is headquartered in Los Angeles, CA. | Health Technology |
American Society for Clinical Investigation
American Society for Clinical Investigation BiotechnologyHealth Technology American Society for Clinical Investigation engages as a medical honor society. It focuses on physician-scientists in research, clinical care, and medical education. The company was founded by Samuel J. Meltzer in 1908 and is headquartered in Ann Arbor, MI. | Health Technology |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Hagop Youssoufian
